Fosun Pharmaceutical Chairman proposes to repurchase company shares to promote high-quality development of the company, with a total amount of 1-2 billion yuan.

On March 1, 2024, Shanghai Fosun Pharmaceutical (600196.SH) announced that the Chairman Wu Yifang proposed to repurchase company shares with a total amount not less than 100 million yuan and not exceeding 200 million yuan, and actively promote lean operation and other management measures to continuously improve efficiency and provide shareholders with stable and sustainable returns. According to the announcement, the repurchase price shall not exceed 30 yuan per share, and the repurchased shares will be used for the company's subsequent implementation of the equity incentive plan, employee stock ownership plan, and other purposes allowed by laws, regulations, and the Articles of Association of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Shanghai Fosun Pharmaceutical stated that in the future, it will continue to implement the action plan of "improving efficiency, returning profits" from five aspects: lean operation, standardized operation, emphasis on shareholder returns, strengthening investor relations, and adhering to sustainable development, actively practicing the development concept of "investors first" for listed companies and safeguarding the interests of all shareholders of the company. Established in 1994, Shanghai Fosun Pharmaceutical has become one of the industry innovation leaders of China Meheco Group after 30 years of development. Shanghai Fosun Pharmaceutical has always focused on the patient, advancing multiple innovative achievements efficiently around unmet clinical needs, insisting on the path of international development with open innovation, and being the first in China to market a number of high-value innovative products. This includes successfully bringing its independently developed artemisinin-based products to the international market, thereby assisting in the prevention and control of malaria in Africa and reducing malaria mortality rates; launching the first domestic CAR-T cell therapy product Yikaida, and pioneering the implementation of a "payment plan based on treatment efficacy value" centered on the patient, allowing high-quality CAR-T products to benefit more patients; continuously exploring and achieving the localization of Da Vinci surgery Siasun Robot & Automation and other endeavors.